Professional Certificate in Pharmacovigilance (PCPV)

0+ Participants
0+ Cities
0+ Countries
0+ Years of Excellence

Pharmacovigilance is the pharmacological sciences relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term side effects of the therapeutic drugs, devices and biologics. Professional Certificate in Pharmacovigilance (PCPV) program is aimed at imparting knowledge and skills required for the pharmacovigilance profession.



gcp training institutes in Delhi Program Highlights


  • Self-learning study modules/Matchbook course
  • Assignment based evaluation
  • Self-paced schedule (1-6 months)
  • Optimal course fee
  • Industry-wide recognition
  • Placement assistance through regular job postings (via WhatsApp)

pharmacovigilance training Eligibility


Candidates who are currently pursuing or have completed following curriculum are eligible for enrolment:

  • B.Pharm, M.Pharm, PhD
  • MBBS, MD, DNB, DM
  • BDS, MDS
  • BAMS, BHMS, BUMS
  • BPT, MPT
  • Life Sciences: B.Sc, M.Sc, Biotechnology
  • Working Professionals


Pharmacovigilance training institutes in Delhi Program Fee


Indian Participants

Rs. 15500

Indian Participants Residing Overseas

Rs. 18500

Foreign Nationals

US$ 325

Register Now

Enrolments open throughout the year

For more information mail at info@catalystclinicalservices.com or contact Program Coordinator at +91 9818356273

Catalyst Clinical Services Pvt. Ltd.
UG-11, Aggarwal Prestige Mall, Plot No. 02, Road No. 44, Pitampura, New Delhi – 110034
Ph: +91-9818356273, +91-8826806862; Email: info@catalystclinicalservices.com

Professional Certificate in Pharmacovigilance, PCPV, Gcp training institutes in Delhi, Pharmacovigilance training, Pharmacovigilance training institutes in Delhi, Clinical research training institute in India, Diploma in clinical research, Certified clinical research professional, Post graduate diploma in clinical research, Clinical course, Pharmacovigilance course fee, Clinical research companies, Pharmacovigilance